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Abstract
We examined the effect of imipramine (a tricyclic antidepressant drug) on hydroxyl radical (OH) generation induced by 1-methyl-4-
phenylpyridinium ion (MPP + ) in extracellular fluid of rat striatum, using a microdialysis technique. Imipramine enhanced the formation
of OH trapped as 2,3-dihydroxybenzoic acid (DHBA) induced by MPP + (5 mM). Introduction of imipramine (0.1, 0.5 and 1.0 mM)
dose-dependently increased the level of dopamine (DA) release. Concomitantly, imipramine enhanced DA efflux and the level of DHBA
induced by MPP +, as compared with MPP + -treated control. When corresponding experiments were performed with reserpinized rats,
there were small increases in the levels of DA and nonsignificant increase in the formation of DHBA. When iron (II) was administered to
imipramine (1 mM)-treated animals, a marked elevation of DHBA was observed, compared with MPP + -only treated animals. A positive
linear correlation was observed between iron (II) and DHBA (R2 = 0.985) in the dialysate. These results indicate that imipramine enhances
generation of OH induced by MPP + during enhanced DA overflow.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Imipramine; 1-Methyl-4-phenylpyridinium ion (MPP+); Dopamine; Hydroxyl radical; Parkinson’s disease
1. Introduction
Various antidepressant drugs have been developed and
their antidepressive effects have been observed in animal
model [1]. It has been demonstrated that tricyclic antide-
pressant drugs inhibit monoamine oxidase (MAO; EC
1.4.3.4) in vitro [2–4]. MAO exists in two forms, form A
(MAO-A) and form B (MAO-B), based on its substrate
specificity and sensitivity to inhibitors [5,6]. MAO-A pref-
erentially deaminates 5-hydroxytryptamine (5-HT), whereas
MAO-B deaminates h-phenylethylamine (h-PEA). 1-
Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produ-
ces a parkinsonian syndrome after its conversion to 1-
methyl-4-phenylpyridinium ion (MPP + ) by MAO-B in
the brain [7,8]. It has been shown that MAO-A is the major
enzyme responsible for the deamination of dopamine (DA)
in the rat striatum [9]. Although there are many papers
showing that DA autoxidation and oxidative stress may be
involved in Parkinson’s disease [10–12], the etiology of
Parkinson’s disease still remains obscure.
Autoxidation and MAO-dependent oxidation of DA can
lead to the formation of reactive cytotoxic free radicals whose
generation could be influenced by the antidepressants
because these antidepressants could inhibit catecholamine
uptake andMAO activities. We as well as others reported that
MPP + induces a massive release of DA in the striatum,
which leads to increased free radicals [11,13,14]. In dopami-
nergic nerve cells, free radicals are mainly generated byMAO
via deamination of DA and nonenzymatically by the autox-
idation of DA [15]. The present study focuses on the effect of
imipramine (tricyclic antidepressant drug) on hydroxyl rad-
ical (OH) generation induced by MPP + in rat striatum.
2. Materials and methods
2.1. Animals
Adult female Wistar rats weighing 300–400 g were kept
in an environmentally controlled room (20–23 jC, 50–60%
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humidity, illuminated from 07:00 to 19:00) and fed food and
water ad libitum. At the end of the experiments the rats were
sacrificed using an overdose of anesthetic. All procedures in
dealing with the experimental animals met the guideline
principles stipulated by the Physiological Society of Japan
and the Animal Ethics Committee of the Oita Medical
University.
2.2. Chemicals
Imipramine hydrochloride was purchased from Ciba-
Geigy (Takarazuka, Japan). MPP + was purchased from
Research Biochemicals Inc., MA, USA. Sodium salicylate
and its hydroxylated metabolites were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). All other
chemicals were obtained from Wako Pure Chemical Indus-
tries (Osaka, Japan). The two radiochemical substrates used
in this study, 5-hydroxytryptamine binoxalate ([2-14C]-5-
HT; 1.48–2.22 Gbq/mmol) and h-phenylethylamine hydro-
chloride ([ethyl-1-14C]-h-PEA, 1.48–2.22 Gbq/mmol),
were purchased from Dupont NEN (New England Nuclear)
Products (Boston, MA, USA). In the case of reserpinized
rats, reserpine (5 mg/kg; Daiichi Pharmaceutical, Japan) was
injected intravenously into the rats 24 h before the experi-
ments.
2.3. Experimental protocol
2.3.1. Assay of MAO activity
The rats were killed by decapitation and the brains were
quickly removed and homogenated in 10 ml of 10 mM
phosphate buffer, pH 7.4, containing 0.32 mM sucrose
solution. To examine the effects of imipramine on MAO
activity in vitro, the enzyme was preincubated for 20 min at
25 jC with imipramine (0.001 to 1.0 mM) before adding the
substrates. Final concentrations of substrate (5-HT for
MAO-A, and h-PEA for MAO-B) were 100 and 10 AM,
respectively. The remaining MAO activity was measured by
adding 20 Al of substrate solution and the mixture was
incubated for 20 min at 37 jC. The reaction was stopped by
adding 2 N HCl (200 Al). The reaction products were
extracted with ethyl acetate–benzene mixture (1:1, v/v)
saturated with water, and the radioactivity in the extract
was measured using Beckmann LS-9000 scintillation coun-
ter. The protein concentrations of the enzyme preparations
were measured according to the method of Lowry et al. [16]
using bovine serum albumin as a standard. The data were
corrected using protein concentration, and expressed as
percent, compared to control (100%). One hundred percent
of MAO-A and -B activities were 0.072F 0.03 and
1.02F 0.05 nmol/min/mg protein, respectively.
2.3.2. Microdialysis experiments
The rats were anaesthetized with chloral hydrate (400
mg/kg, i.p.), and the level of anaesthesia was maintained by
intraperitoneal injection of chloral hydrate (20 mg/kg).
Ringer’s solution containing 147 mM NaCl, 2.3 mM CaCl2
and 4 mM KCl, pH 7.0, was used for perfusion (1 Al/min)
through a microdialysis probe into the striatum. The recov-
ery rate of 0.1 AM DAwas 20.8F 0.9% at flow rate of 1 Al/
min. The microdialysis probe was pre-washed with Ringer’s
solution for at least 30 min prior to stereotaxical implanta-
tion in the striatum (stereotaxic coordinates: AP: 1.0, R/L:
2.5, H:  7 mm from dura matter) [17]. Thereafter, sodium
salicylate in Ringer’s solution (0.5 nmol/Al/min) was per-
fused by a microinjection pump (Carnegie Medicine CMA/
100, Stockholm, Sweden) to trap OH radicals [18,19] in
the striatum, and basal levels of dihydroxybenzoic acid
(DHBA) were determined during a definite period. Brain
dialysate (1 Al/min) was collected every 15 min in small
tubes containing 15 Al of 0.1 N HClO4 to prevent amine
oxidation and assayed immediately for DHBA by high-
performance liquid chromatography with electrochemical
(HPLC-EC) procedure [18–20]. The dialysate samples were
promptly injected into an HPLC-EC system equipped with a
glassy carbon working electrode (Eicom, Kyoto, Japan) and
an analytic reverse-phase column on an Eicompak MA-
5ODS column (5 Am, 4.6F 150 mm; Eicom). The working
electrode was set at a detection potential of 0.75 V.
2.4. Statistical analysis
All values are presented as meansF S.E. The signifi-
cance of difference was determined by using ANOVA with
Fisher’s post-hoc test. A P value of less than 0.05 was
regarded as being statistically significant.
3. Results
3.1. Effect of imipramine on MAO activity in vitro
To determine the mechanism by which MAO activity
was inhibited by imipramine, the effects of various concen-
Fig. 1. Inhibition of MAO activity in rat brain by imipramine. After
incubation at 25 jC for 20 min with imipramine (0.001, 0.01, 0.1 and 1
mM), MAO activities were determined using 100 AM 5-HT (closed circle)
or 10 AM h-PEA (open circle) as substrate at 37 jC for 20 min. Values are
expressed as percent control. The results are meanF S.E. for five animals.
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trations of imipramine on MAO in rat brain homogenates
were studied in vitro using 5-HT and h-PEA as substrates.
Imipramine (0.001, 0.01, 0.1 and 1 mM) inhibited both
MAO-A and -B activities in a dose-dependent manner.
When the brain homogenates were preincubated at 25 jC
for 20 min with imipramine, the residual activity of MAO-A
and MAO-B activities with 100 AM imipramine were 63%
and 4%, respectively (Fig. 1). However, 1 mM imipramine
completely inhibited both MAO activities.
3.2. Effect of imipramine on OH generation induced by
MPP+
After a 60-min washout with pH 7.4 Ringer’s solution,
the striatum was infused with MPP + (5 mM) for 15 min
(total dose 75 nmol). When 1 mM imipramine was intro-
duced into the dialysate, time-dependent changes in the
level of DA and the formation of DHBA from OH were
monitored in the dialysates from rat brain after MPP +
treatment. Although imipramine (1 mM) alone did not
induced DA efflux, imipramine (1 mM) enhanced the level
of DA induced by MPP + (Fig. 2A). Introduction of imipr-
amine drastically enhanced MPP + -induced DA release with
concomitant increase in OH formation trapped as DHBA in
the brain dialysate, compared with MPP + -only treated ani-
mals. At 90 and 105 min, imipramine significantly increased
DHBA formation as shown in Fig. 2B (P < 0.05). When
corresponding experiments were performed with reserpi-
nized rats, small increases in the level of DA (Fig. 3A) and
nonsignificant increase in the formation of DHBA were
Fig. 2. Effect of MPP + on the release of DA and the formation of OH
after imipramine treatment in the striatum of rats. After a 60-min washout
with Ringer’s solution (pH 7.4), striatum was infused with MPP + (5 mM)
for 15 min (solid bat; total dose, 75 nmol) to evoke the release of DA (A).
Then, at 60 min after probe implantation, sodium salicylate (hatched bar;
0.5 nmol/Al/min) was infused through the microdialysis probe for 90 min to
trap OH (B). Brain dialysates were collected every 15 min in 0.1 N HClO4
and immediately assayed by an HPLC-EC. MPP + (open circle), MPP + and
1 mM imipramine (closed circle), and no MPP + (rectangle) were com-
pared. Values are meansF S.E. for five animals. Both the total DA efflux
and DHBA formation elicited by imipramine were significantly elevated
over that of MPP + alone group ( P < 0.05 for MPP + alone vs. MPP + and
1 mM imipramine: ANOVA and Fisher’s test).
Fig. 3. Effect of MPP + on the release of DA and the formation of OH
after imipramine treatment by reserpinized rats. Experimental conditions
and symbols are the same as for Fig. 2.
Fig. 4. Dose-dependent effects of imipramine on the level of DA in the
MPP + -treated rat striatum. The level of DA measured at 30–45 min after
application of various concentrations of imipramine (as indicated abscissa)
(hatched column) are given as a percentage of the value measured just
before application of imipramine. Each column and vertical bar indicates
meanF S.E. The number in the parentheses indicates the number of
animal. *P < 0.05 versus the level of DA immediately before application of
imipramine (ANOVA and Fisher’s test).
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observed (Fig. 3B). As shown in Fig. 4, imipramine (0.01,
0.1 and 1.0 mM) dose-dependently increased the level of
DA release. At 1 mM of imipramine, the increase in DAwas
statistically significant (P < 0.05, n = 5). To confirm whether
the OH generation was based on a Fenton-type reaction,
iron (II) was infused through the dialysis probe. When iron
(II) (2, 5 and 10 AM) was administered to MPP + -pretreated
animals, iron (II) clearly produced a dose-dependent
increase in the levels of DHBA, showing a positive linear
correlation between iron (II) and OH formation trapped as
DHBA (R2 = 0.985) in the dialysate, as compared with the
iron (II)-only treated group (Fig. 5). The data suggest that
the effect of imipramine on OH formation was based on the
Fenton-type reaction.
4. Discussion
We have demonstrated that imipramine (a tricyclic anti-
depressant drug) enhances generation of OH induced by
MPP + in the extracellular space of the striatum. It is known
that tricyclic antidepressant drugs inhibited MAO activities
and that, in vitro, these drugs are more potent inhibitors of
MAO-B than MAO-A [3,4]. MAO is a brain enzyme that
plays a role in the metabolism of various catecholamine.
Both MAO-A and MAO-B activities in rat brain were
inhibited by imipramine (Fig. 1). Kato et al. [21] reported
that MAO inhibitor caused the accumulation of DA in the
extracellular fluid. We previously reported [3] that the level
of the oxidized DA metabolite DOPAC decreased following
the administration of imipramine. This result indicates that
imipramine increased the level of DA. MAO is one of the
enzymes metabolizing various neurotransmitter monoamines
[14]. If MPP + or its related compound(s) is responsible for
inducing Parkinson disease, inhibition of MAO-B may lead
to induce protective effect against OH formation [22]. It
was reported that the MAO-B inhibitors can diminish neuro-
nal cell death [23]. In rat brain, MPP + is a more potent
MAO-A inhibitor than MAO-B [24], and MAO-A is pre-
dominantly responsible for striatal DA oxidation [21]. On the
contrary, in human brain, MAO-B is responsible for DA
oxidation [25,26]. The DA that accumulates in the extra-
cellular fluid following administration of antidepressants can
undergo autoxidation, which in turn leads (possibly by an
indirect mechanism) to the formation of cytotoxic OH free
radicals. As shown in the present study, the antidepressant
inhibited MAO activities in vitro. Antidepressant drugs have
heretofore been considered effective in the treatment of
depression because they inhibit the active uptake of amines
in the presynaptic cells of the brain [27,28]. Imipramine is
also potent inhibitors of DA reuptake. Regardless of their
specific mechanisms of action, the consequence is increased
extracellular levels of DA. This may explain the observed
increase in OH. Both nonenzymatic and enzymatic mecha-
nisms may contribute to free radical formation induced by
antidepressant drugs in the striatum in vivo.
The concentration profile of the administered compounds
in the surrounding interstitial space is unknown: in general,
the extracellular concentration of a compound given through
the probe would never reach the concentration in the
dialysis probe. This is an unavoidable limitation of the
microdialysis technique that should be kept in mind when
interpreting the experimental data. Introduction of imipr-
amine (1 mM) drastically increased the DA efflux and the
level of DHBA induced by MPP + (Fig. 2). Although there
are many reports about the effect of MPP + on OH
generation, the mechanism of OH generation by MPP +
is obscure. Free radical formation enhanced by MPP + in the
striatum appeared to be dose-dependent and positively
correlated with amounts of sustained DA overflow [13].
DA is known to be autoxidated in the presence of oxygen
and transition metal [12,29]. When imipramine concentra-
tion in the perfusate was increased, DA efflux was enhanced
with concomitant increase in OH formation. Our obtained
data demonstrated that sustained DA overflow elicited by
imipramine in the striatum also led to enhanced MPP + -
induced OH formation. These data are consistent with the
notion that DA autoxidation and sustained DA turnover can
lead to free radical formation, which in turn causes oxidative
damage in the iron-enriched nigral neuron during senes-
cence and Parkinson’s diseases [12,13]. This evoked DA
overflow was enhanced by imipramine. The levels of DA
and DHBA in reserpinized rats were drastically reduced, as
compared with that of imipramine and MPP + -treated
groups (Fig. 3). The results also suggest that the mechanism
of imipramine and MPP + -induced OH formation was via
DA efflux. The present study demonstrated that imipramine
increased OH formation in the extracellular space of the
Fig. 5. Cumulative dose– response relationship between iron (II) and the
formation of OH products of salicylic acid with and without MPP +
treatment. Iron (II) and sodium salicylate (0.5 nmol/Al/min) were infused
through the dialysis probe. Three different concentrations of iron (II) (2, 5
and 10 AM) were infused through the probe placed in the imipramine (1
mM)-treated rats, and the levels of DHBA were measured. The ordinate
shows the cumulative level of DHBA output over 90 min. MPP + (open
circle), MPP + and 1 mM imipramine (closed circle), MPP + and no MPP +
(rectangle) were compared. Values are meansF S.E. for four animals.
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striatum with concomitant DA release. Therefore, imipr-
amine increased the OH formation trapped as DHBA.
Moreover, to confirm whether the imipramine-evoked OH
generation in the MPP + -treated rats was based on the
Fenton-type reaction, the DHBA formation was measured
in the presence of iron in imipramine- and MPP + -treated
rats. Iron (II) clearly produced a dose-dependent increase in
the levels of DHBA (Fig. 5). This finding indicates that
extracellular DA is needed for the observed effect of
Fenton-type reaction.
MPP + causes a sustained DA release into extraneuronal
space, generating oxygen free radicals with extracellular DA
autoxidation [11]. This could lead to the formation of OH
radicals, which may induce lipid peroxidation, protein cross-
linking and DNA damage, mediated by base pair mutation
[30]. If toxic species are being produced on Parkinson’s
disease, they would normally be inactivated by a variety of
protective mechanisms, but the mechanisms, however, may
be impaired in the substantia nigra of patients with Parkin-
son’s disease; reduced levels of, e.g., catalase and gluta-
thione (GSH) [31]. The enzyme MAO is one of the enzymes
metabolizing various neurotransmitter monoamines [14].
Among MAO-B inhibitors, L-deprenyl is widely used for
the treatment of patients with Parkinson’s disease. Inhibition
of MAO-B may be involved in its protective effect [22], if
MPP + or related compound(s) is responsible for inducing
Parkinson’s disease. It is clear that MAO-B is responsible
for the production of MPP +. Therefore, the MAO-B inhib-
itors can diminish neuronal cell death [23].
DA is known to be autoxidized in the presence of oxygen
and iron (II), and to be converted to semiquinone, quinone,
zwitteric 5,6-dihydroxyindoles and melanin [11]. The DA
efflux was enhanced imipramine and MPP + administration.
DA is known to undergo autoxidation in the presence of
oxygen and iron (II) [13,29]. Normally, iron (III) is bound to
endogenous chelators such as ADP and, in the absence of a
significant amount of ferritin in the substantia nigra, could
be chelated by melanin. Increased concentrations of DA
could serve as the catalyst for the conversion of iron (III) to
iron (II) by melanin and, in the presence of H2O2, results in
further formation of OH, depending on the environmental
conditions [32]. The production of OH in the presence of
melanin is significantly greater when iron (III) is predom-
inant [32], and is further demonstrated by the greater lipid
peroxidation of rat cerebral cortex in the presence of iron
(II) and higher DA melanin concentrations [33]. An
enhanced generation of cytotoxic OH radicals through
DA accumulation could accelerate the MPP + -induced
degeneration of nigral neurons. Accordingly, imipramine
enhances generation of OH induced by MPP + during
enhanced DA overflow.
In conclusion, a tricyclic antidepressant drug may play a
key role in OH formation by the release of DA from
nigrostriatal nerves in the brain by the action of MPP +.
The results in the experiment may be useful for elucidating
the actual mechanism of free radical formation in the patho-
genesis of neurodegenerative brain disorders including Par-
kinson’s disease, Alzheimer’s disease and traumatic brain
injuries.
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